Table 2.

Baseline and end of project vaccination rates

	Intervention (n = 23), mean ± SD	Comparator (n = 20), mean ± SD	P-value	HP 2020 Intervention (n*)	HP2020 Comparator (n*)
Y1 Influenza	44.4% ± 16.7%	35.1% ± 19.1%	0.096	1	0
Y2 Influenza	51.3% ± 12.9%	41.3% ± 14.3%	0.019	1	1
Y1 Pneumococcal (Age)	62.8% ± 17.7%	55.9% ± 19.0%	0.223	8	1
Y2 Pneumococcal (Age)	81.4% ± 16.6%	72.6% ± 18.4%	0.106	14	9
Y1 Pneumococcal (Risk)	35.7% ± 19.4%	24.3% ± 20.1%	0.066	3	3
Y2 Pneumococcal (Risk)	34.5% ± 19.0%	28.2% ± 20.0%	0.0295	3	4
Y1 Zoster	37.1% ± 13.4%	35.0% ± 18.7%	0.671	19	11
Y2 Zoster	41.9% ± 13.1%	42.3% ± 20.9%	0.940	19	11

Y1- baseline vaccination rates; Y2 - end-of-study vaccination rates; HP2020 - Healthy People 2020; n* - number of providers who reached HP2020 target by the end of intervention period; p-value for independent samples t-test of difference between groups at each time point, unadjusted for baseline rates